J. Goldman & Co’s Celularity CELU Stock Holding History

J. Goldman & Co’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,000	Closed	-$275K	–	446
2020 Q4	$275K	Hold	10,000	–	–	0.01%	315
2020 Q3	$158K	Hold	10,000	–	–	0.01%	288
2020 Q2	$106K	Hold	10,000	–	–	0.01%	251
2020 Q1	$48K	Hold	10,000	–	–	0.01%	230
2019 Q4	$78K	Sell	10,000 -12,500	-56%	-$1.24M	0.01%	245
2019 Q3	$132K	Buy	+22,500	New	+$2.21M	0.01%	264

Other funds holding CELU

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MSU

Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

J. Goldman & Co's CELU Position: Q1 2021 in Review

J. Goldman & Co sold out of Celularity (CELU) in Q1 2021, closing a stake of 18,000 shares — an estimated $1.98M sold.

J. Goldman & Co first reported a position in CELU in Q3 2019 and held it in 6 quarters. The position peaked at $2.1M in Q3 2020. 63 funds tracked by Wall St. Rank hold CELU as of Q1 2021.

J. Goldman & Co reported no remaining Celularity position as of Q1 2021 after selling out during the quarter.
J. Goldman & Co sold 18,000 Celularity shares in Q1 2021, an estimated $1.98M.
J. Goldman & Co first reported a position in Celularity in Q3 2019 and held it in 6 quarters.
J. Goldman & Co's Celularity position peaked at $2.1M in Q3 2020.
63 funds tracked by Wall St. Rank held Celularity as of Q1 2021.

Based on J. Goldman & Co's 13F filing for Q1 2021, filed 17 May 2021.